BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 12167711)

  • 1. Hypophosphorylation of Mdm2 augments p53 stability.
    Blattner C; Hay T; Meek DW; Lane DP
    Mol Cell Biol; 2002 Sep; 22(17):6170-82. PubMed ID: 12167711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MDMX stability is regulated by p53-induced caspase cleavage in NIH3T3 mouse fibroblasts.
    Gentiletti F; Mancini F; D'Angelo M; Sacchi A; Pontecorvi A; Jochemsen AG; Moretti F
    Oncogene; 2002 Jan; 21(6):867-77. PubMed ID: 11840332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycogen synthase kinase 3-dependent phosphorylation of Mdm2 regulates p53 abundance.
    Kulikov R; Boehme KA; Blattner C
    Mol Cell Biol; 2005 Aug; 25(16):7170-80. PubMed ID: 16055726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDM2 promotes ubiquitination and degradation of MDMX.
    Pan Y; Chen J
    Mol Cell Biol; 2003 Aug; 23(15):5113-21. PubMed ID: 12860999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1.
    Asher G; Lotem J; Sachs L; Kahana C; Shaul Y
    Proc Natl Acad Sci U S A; 2002 Oct; 99(20):13125-30. PubMed ID: 12232053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The MDM2-p53 interaction.
    Moll UM; Petrenko O
    Mol Cancer Res; 2003 Dec; 1(14):1001-8. PubMed ID: 14707283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphorylation of murine double minute clone 2 (MDM2) protein at serine-267 by protein kinase CK2 in vitro and in cultured cells.
    Hjerrild M; Milne D; Dumaz N; Hay T; Issinger OG; Meek D
    Biochem J; 2001 Apr; 355(Pt 2):347-56. PubMed ID: 11284721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Critical role for a central part of Mdm2 in the ubiquitylation of p53.
    Meulmeester E; Frenk R; Stad R; de Graaf P; Marine JC; Vousden KH; Jochemsen AG
    Mol Cell Biol; 2003 Jul; 23(14):4929-38. PubMed ID: 12832478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase.
    Lin HK; Wang L; Hu YC; Altuwaijri S; Chang C
    EMBO J; 2002 Aug; 21(15):4037-48. PubMed ID: 12145204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53.
    Fang S; Jensen JP; Ludwig RL; Vousden KH; Weissman AM
    J Biol Chem; 2000 Mar; 275(12):8945-51. PubMed ID: 10722742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo.
    Shimizu H; Burch LR; Smith AJ; Dornan D; Wallace M; Ball KL; Hupp TR
    J Biol Chem; 2002 Aug; 277(32):28446-58. PubMed ID: 11925449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding.
    Wang W; Takimoto R; Rastinejad F; El-Deiry WS
    Mol Cell Biol; 2003 Mar; 23(6):2171-81. PubMed ID: 12612087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo.
    Xirodimas D; Saville MK; Edling C; Lane DP; LaĆ­n S
    Oncogene; 2001 Aug; 20(36):4972-83. PubMed ID: 11526482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo.
    Midgley CA; Desterro JM; Saville MK; Howard S; Sparks A; Hay RT; Lane DP
    Oncogene; 2000 May; 19(19):2312-23. PubMed ID: 10822382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation.
    Jin Y; Lee H; Zeng SX; Dai MS; Lu H
    EMBO J; 2003 Dec; 22(23):6365-77. PubMed ID: 14633995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation.
    Ito A; Kawaguchi Y; Lai CH; Kovacs JJ; Higashimoto Y; Appella E; Yao TP
    EMBO J; 2002 Nov; 21(22):6236-45. PubMed ID: 12426395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation.
    Rodriguez MS; Desterro JM; Lain S; Lane DP; Hay RT
    Mol Cell Biol; 2000 Nov; 20(22):8458-67. PubMed ID: 11046142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-terminal polyubiquitination and degradation of the Arf tumor suppressor.
    Kuo ML; den Besten W; Bertwistle D; Roussel MF; Sherr CJ
    Genes Dev; 2004 Aug; 18(15):1862-74. PubMed ID: 15289458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53.
    Honda R; Yasuda H
    EMBO J; 1999 Jan; 18(1):22-7. PubMed ID: 9878046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ubiquitin ligase COP1 is a critical negative regulator of p53.
    Dornan D; Wertz I; Shimizu H; Arnott D; Frantz GD; Dowd P; O'Rourke K; Koeppen H; Dixit VM
    Nature; 2004 May; 429(6987):86-92. PubMed ID: 15103385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.